The Cedar Project: mortality among young Indigenous people who use drugs in British Columbia
- PMID: 29109208
- PMCID: PMC5675541
- DOI: 10.1503/cmaj.160778
The Cedar Project: mortality among young Indigenous people who use drugs in British Columbia
Abstract
Background: Young Indigenous people, particularly those involved in the child welfare system, those entrenched in substance use and those living with HIV or hepatitis C, are dying prematurely. We report mortality rates among young Indigenous people who use drugs in British Columbia and explore predictors of mortality over time.
Methods: We analyzed data collected every 6 months between 2003 and 2014 by the Cedar Project, a prospective cohort study involving young Indigenous people who use illicit drugs in Vancouver and Prince George, BC. We calculated age-standardized mortality ratios using Indigenous and Canadian reference populations. We identified predictors of mortality using time-dependent Cox proportional hazard regression.
Results: Among 610 participants, 40 died between 2003 and 2014, yielding a mortality rate of 670 per 100 000 person-years. Young Indigenous people who used drugs were 12.9 (95% confidence interval [CI] 9.2-17.5) times more likely to die than all Canadians the same age and were 7.8 (95% CI 5.6-10.6) times more likely to die than Indigenous people with Status in BC. Young women and those using drugs by injection were most affected. The leading causes of death were overdose (n = 15 [38%]), illness (n = 11 [28%]) and suicide (n = 5 [12%]). Predictors of mortality included having hepatitis C at baseline (adjusted hazard ratio [HR] 2.76, 95% CI 1.47-5.16), previous attempted suicide (adjusted HR 1.88, 95% CI 1.01-3.50) and recent overdose (adjusted HR 2.85, 95% CI 1.00-8.09).
Interpretation: Young Indigenous people using drugs in BC are dying at an alarming rate, particularly young women and those using injection drugs. These deaths likely reflect complex intersections of historical and present-day injustices, substance use and barriers to care.
© 2017 Joule Inc. or its licensors.
Conflict of interest statement
Competing interests: Eric Yoshida has been an investigator for clinical trials (outside the work reported here) sponsored by Abbvie, Gilead Sciences Inc., Merck Inc., Janssen Inc., Springbank Inc., Intercept Inc. and Genfit Inc.; he has also received honoraria for continuing medical education lectures sponsored by Gilead Sciences Canada Inc., Merck Canada Inc. and Celgene Canada Inc. Patricia Spittal has received grants from Gilead for cultural safety supports and from Merck for an HCV blanket program. No other competing interests were declared.
Comment in
-
Need for equity in treatment of substance use among Indigenous people in Canada.CMAJ. 2017 Nov 6;189(44):E1350-E1351. doi: 10.1503/cmaj.171002. CMAJ. 2017. PMID: 29109207 Free PMC article. No abstract available.
References
-
- John E. Indigenous resilience, connectedness and reunification — from root causes to root solutions: a report on Indigenous child welfare in British Columbia. Chilliwack (BC): Ministry of Children and Family Development; 2016.
-
- Christian WM, Spittal PM. The Cedar Project: acknowledging the pain of our children. Lancet 2008;372:1132–3. - PubMed
-
- Attawapiskat chief implores Trudeau for meeting, cites 9 more suicide attempts this week. CBC News; 2016. May 5 Available: www.cbc.ca/news/canada/sudbury/attawapiskat-suicide-attempts-letter-chie... (accessed 2017 Feb. 8).
-
- Fact sheet: urban Aboriginal population in Canada. Ottawa: Indigenous and Northern Affairs Canada; 2016.
-
- The health and well-being of the Aboriginal population: interim update [Provincial Health Officer’s Special Report]. Victoria: Office of the Provincial Health Officer; 2012.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources